Advances in rheumatology: coxibs and beyond

Area of Science:

• Rheumatology
• Pharmacology
• Public Health

Background:

• Arthritis impacts 70 million Americans, with numbers projected to rise due to an aging population.
• Arthritis leads to decreased mobility, reduced quality of life, and increased risk of obesity, heart disease, diabetes, and hypertension.
• No disease-modifying drugs exist for osteoarthritis (OA), making current treatments primarily symptomatic.

Purpose of the Study:

• To review current pharmacological and non-pharmacological treatment strategies for arthritis, including osteoarthritis (OA) and rheumatoid arthritis (RA).
• To highlight the role of anti-inflammatory and analgesic medications in managing arthritis symptoms.
• To emphasize the importance of combining pharmacological treatments with non-pharmacological modalities for optimal patient outcomes.

Main Methods:

• Review of existing literature on arthritis treatment.
• Analysis of pharmacological options, including acetaminophen, NSAIDs, coxibs, and topical agents.
• Evaluation of non-pharmacological interventions such as patient education and exercise programs.

Main Results:

• Acetaminophen, NSAIDs, and simple analgesics are mainstays for OA treatment.
• Coxibs offer potential gastrointestinal (GI) safety benefits over traditional NSAIDs.
• For RA, NSAIDs and coxibs serve as adjuncts to disease-modifying drugs (DMARDs), with caution advised due to GI risks, especially with corticosteroids.

Conclusions:

• Pharmacological treatments for arthritis primarily focus on symptom management.
• Non-pharmacological approaches, including exercise and education, are crucial for delaying joint degradation and maintaining function.
• A combined approach of medication and lifestyle interventions is essential for managing arthritis effectively.